PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26830512-8	2016	When pretreated with a central AADC inhibitor (NSD-1015), further application of l-dopa failed to increase the motoneuron activity although the expression of DA in the AADC cells was not completely inhibited.	3-hydroxybenzylhydrazine	47-55	dopa decarboxylase	Rattus norvegicus	31-35
29935278-6	2019	Tryptophan hydroxylase 2 (TPH2) activity was measured following injection of the aromatic amino acid decarboxylase (AADC)-inhibitor, NSD-1015, and subsequent HPLC detection of 5-hydroxytryptophan (5-HTP) within subregions of the dorsal raphe nucleus (DR) and median raphe nucleus (MnR).	3-hydroxybenzylhydrazine	133-141	tryptophan hydroxylase 2	Mus musculus	0-24
29935278-6	2019	Tryptophan hydroxylase 2 (TPH2) activity was measured following injection of the aromatic amino acid decarboxylase (AADC)-inhibitor, NSD-1015, and subsequent HPLC detection of 5-hydroxytryptophan (5-HTP) within subregions of the dorsal raphe nucleus (DR) and median raphe nucleus (MnR).	3-hydroxybenzylhydrazine	133-141	tryptophan hydroxylase 2	Mus musculus	26-30
27622543-5	2016	induced ptosis under treatment with 3-hydroxybenzylhydrazine, a centrally acting AADC inhibitor.	3-hydroxybenzylhydrazine	36-60	dopa decarboxylase	Mus musculus	81-85
18582514-5	2008	The synthesis of dopamine from L-DOPA supplied to Muller cultures is inhibited by m-hydroxybenzylhydrazine, a DDC inhibitor.	3-hydroxybenzylhydrazine	82-106	dopa decarboxylase	Mus musculus	110-113
23940784-6	2013	Inhibition of Ddc by AADC inhibitor NSD-1015 or anti-sense morpholino oligonucleotides (MO) reduced brain volume and body length.	3-hydroxybenzylhydrazine	36-44	dopa decarboxylase	Danio rerio	14-17
23940784-6	2013	Inhibition of Ddc by AADC inhibitor NSD-1015 or anti-sense morpholino oligonucleotides (MO) reduced brain volume and body length.	3-hydroxybenzylhydrazine	36-44	dopa decarboxylase	Homo sapiens	21-25
23196068-9	2013	Dopamine, ROS production and cell death were attenuated by co-incubation with the AADC inhibitor, NSD-1015.	3-hydroxybenzylhydrazine	98-106	dopa decarboxylase	Rattus norvegicus	82-86
20542064-8	2010	The hyperactivity induced by L-DOPA and NSD1015 was reduced by the alpha(2C) antagonist rauwolscine (1 mg/kg) and the 5-HT(2C) agonist MK212 (5 mg/kg), but not by the D2 dopamine receptor antagonist remoxipride (3 mg/kg) or the D1 dopamine receptor antagonist SCH23390 (1 mg/kg).	3-hydroxybenzylhydrazine	40-47	dopamine receptor D2	Rattus norvegicus	167-187
17437548-2	2007	To study the role of the enzyme tyrosine hydroxylase (TH; EC 1.14.16.2) in this experimental paradigm, we have examined its activity by assessing the accumulation of l-3,4-dihydroxyphenylalanine after inhibiting the subsequent enzyme in the DA synthetic pathway, aromatic l-amino acid decarboxylase, with 3-hydroxybenzylhydrazine.	3-hydroxybenzylhydrazine	305-329	tyrosine hydroxylase	Homo sapiens	32-52
17437548-2	2007	To study the role of the enzyme tyrosine hydroxylase (TH; EC 1.14.16.2) in this experimental paradigm, we have examined its activity by assessing the accumulation of l-3,4-dihydroxyphenylalanine after inhibiting the subsequent enzyme in the DA synthetic pathway, aromatic l-amino acid decarboxylase, with 3-hydroxybenzylhydrazine.	3-hydroxybenzylhydrazine	305-329	tyrosine hydroxylase	Homo sapiens	54-56
16399699-7	2006	Coinfusion of the aromatic amino acid decarboxylase (AADC) inhibitor m-hydroxybenzylhydrazine attenuated these effects in hippocampus and decreased basal extracellular DA in the striatum.	3-hydroxybenzylhydrazine	69-93	dopa decarboxylase	Homo sapiens	53-57
11002293-7	2000	The effect of L-DOPA was unchanged after inhibition of conversion of L-DOPA to dopamine by m-hydroxybenzylhydrazine (NSD-1015), an inhibitor of DOPA decarboxylase, suggesting that L-DOPA itself is working for cell protection.	3-hydroxybenzylhydrazine	91-115	dopa decarboxylase	Rattus norvegicus	144-162
12658372-2	2003	In vitro, carbidopa, benserazide and NSD-1015 all potently inhibited hepatic MAO A and B activity (IC(50) 10-50 micro M).	3-hydroxybenzylhydrazine	37-45	monoamine oxidase A	Rattus norvegicus	77-82
12658372-3	2003	In ex vivo studies following systemic drug administration, NSD-1015 (100 mg/kg ip) produced 88% and 96% inhibition of hepatic and striatal MAO A and B activity respectively.	3-hydroxybenzylhydrazine	59-67	monoamine oxidase A	Rattus norvegicus	139-144
11135014-0	2001	The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.	3-hydroxybenzylhydrazine	62-70	dopa decarboxylase	Rattus norvegicus	32-50
11135014-1	2001	The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA.	3-hydroxybenzylhydrazine	78-103	dopa decarboxylase	Rattus norvegicus	41-59
11135014-1	2001	The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA.	3-hydroxybenzylhydrazine	78-103	dopa decarboxylase	Rattus norvegicus	61-65
11135014-1	2001	The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA.	3-hydroxybenzylhydrazine	105-113	dopa decarboxylase	Rattus norvegicus	41-59
11135014-1	2001	The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA.	3-hydroxybenzylhydrazine	105-113	dopa decarboxylase	Rattus norvegicus	61-65
11135014-13	2001	Pretreatment of rats with the central AADC inhibitor, NSD-1015 (100 mg/kg i.p.	3-hydroxybenzylhydrazine	54-62	dopa decarboxylase	Rattus norvegicus	38-42
11274784-4	2001	Injection of the central aromatic L-amino-acid decarboxylase inhibitor NSD-1015 30min before and 15min after the injection of L-DOPA suppressed the rotational behavior and the striatal induction of Fos.	3-hydroxybenzylhydrazine	71-79	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	198-201
11002293-7	2000	The effect of L-DOPA was unchanged after inhibition of conversion of L-DOPA to dopamine by m-hydroxybenzylhydrazine (NSD-1015), an inhibitor of DOPA decarboxylase, suggesting that L-DOPA itself is working for cell protection.	3-hydroxybenzylhydrazine	117-125	dopa decarboxylase	Rattus norvegicus	144-162
9798728-7	1998	Twenty minutes later, m-hydroxybenzylhydrazine (NSD), a DOPA decarboxylase inhibitor, was administered.	3-hydroxybenzylhydrazine	22-46	dopa decarboxylase	Rattus norvegicus	56-74
10215890-2	1999	In this study, the intracellular activity of tryptophan hydroxylase was assessed by applying 3-hydroxybenzylhydrazine (NSD-1015), an inhibitor of aromatic l-amino acid decarboxylase, to monolayer cultures of RBL2H3 cells, a serotonin producing mast cell line.	3-hydroxybenzylhydrazine	93-117	RB transcriptional corepressor like 2	Rattus norvegicus	208-212
10215890-2	1999	In this study, the intracellular activity of tryptophan hydroxylase was assessed by applying 3-hydroxybenzylhydrazine (NSD-1015), an inhibitor of aromatic l-amino acid decarboxylase, to monolayer cultures of RBL2H3 cells, a serotonin producing mast cell line.	3-hydroxybenzylhydrazine	119-127	RB transcriptional corepressor like 2	Rattus norvegicus	208-212
10742291-3	2000	We now investigate the effects of the centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor NSD-1015 (3-hydroxybenzyl hydrazine) on the motor actions of L-DOPA and dopamine agonist drugs in MPTP treated common marmosets.	3-hydroxybenzylhydrazine	121-146	aromatic-L-amino-acid decarboxylase	Callithrix jacchus	75-93
10190142-9	1998	Intrastriatal perfusion of NSD-1015, a central DOPA decarboxylase inhibitor, at 30 microM 10 min before ischemia, markedly increased DOPA and glutamate release by ischemia with slight inhibition of dopamine release and exaggerated delayed neuronal cell death in striata.	3-hydroxybenzylhydrazine	27-35	dopa decarboxylase	Rattus norvegicus	47-65
9062867-6	1997	The detected enzyme activities were sensitive to specific inhibitors of HDC (alpha-fluoromethylhistidine and alpha-hydrazinohistidine) and HMT (quinacrine and metoprine); inhibitors of aromatic amino acid decarboxylase alpha-methyl-DOPA and NSD-1015 were inactive on HDC.	3-hydroxybenzylhydrazine	241-249	histidine decarboxylase	Gallus gallus	72-75
9555017-5	1998	In response to NSD-1015 (an inhibitor of aromatic L-amino acid decarboxylase, AADC), 5-hydroxytryptophan (5-HTP) levels were substantially elevated in the SN grafted striata as compared with those in the sham grafted controls, which continued even after subsequent administration of L-3,4-dihydroxyphenylalanine (L-DOPA, 100 mg/kg i.p.).	3-hydroxybenzylhydrazine	15-23	dopa decarboxylase	Rattus norvegicus	78-82
9062867-6	1997	The detected enzyme activities were sensitive to specific inhibitors of HDC (alpha-fluoromethylhistidine and alpha-hydrazinohistidine) and HMT (quinacrine and metoprine); inhibitors of aromatic amino acid decarboxylase alpha-methyl-DOPA and NSD-1015 were inactive on HDC.	3-hydroxybenzylhydrazine	241-249	histidine decarboxylase	Gallus gallus	267-270
7626719-11	1995	After treatment with aromatic amino acid decarboxylase inhibitor NSD-1015 on Day 7 p.c., plasma levels of PRL were similarly elevated in transgenic and normal females.	3-hydroxybenzylhydrazine	65-73	prolactin	Mus musculus	106-109
8576911-6	1996	The rate constant for formation of the enzyme-inhibitor complex determined from the slow-binding kinetics was 2.08 x 10(3) and 1.98 x 10(4) M-1 min-1 for methylhydrazine and (3-hydroxybenzyl)hydrazine, respectively.	3-hydroxybenzylhydrazine	174-200	myoregulin	Homo sapiens	140-149
8576911-19	1996	Only 1 PLP/enzyme dimer reacted with methylhydrazine or (3-hydroxybenzyl)hydrazine, as indicated by Scatchard plots, or with 3-hydrazinopropionate, as shown by a spectrophotometric titration.	3-hydroxybenzylhydrazine	56-82	pyridoxal phosphatase	Homo sapiens	7-10
8752116-2	1996	The present study uses multiple selective Ca2+ channel and protein kinase agonists and antagonists to elucidate the mechanisms by which NPY modulates catecholamine synthesis as determined by in situ measurement of DOPA production in the presence of the decarboxylase inhibitor m-hydroxybenzylhydrazine (NSD-1015).	3-hydroxybenzylhydrazine	277-301	neuropeptide Y	Rattus norvegicus	136-139
8752116-2	1996	The present study uses multiple selective Ca2+ channel and protein kinase agonists and antagonists to elucidate the mechanisms by which NPY modulates catecholamine synthesis as determined by in situ measurement of DOPA production in the presence of the decarboxylase inhibitor m-hydroxybenzylhydrazine (NSD-1015).	3-hydroxybenzylhydrazine	303-311	neuropeptide Y	Rattus norvegicus	136-139
8576911-1	1996	(3-Hydroxybenzyl)hydrazine and methylhydrazine have been found to be potent slow-binding inhibitors of the pyridoxal 5-phosphate (PLP)-dependent enzyme gamma-aminobutyric acid aminotransferase (GABA-AT).	3-hydroxybenzylhydrazine	0-26	pyridoxal phosphatase	Homo sapiens	130-133
8576911-1	1996	(3-Hydroxybenzyl)hydrazine and methylhydrazine have been found to be potent slow-binding inhibitors of the pyridoxal 5-phosphate (PLP)-dependent enzyme gamma-aminobutyric acid aminotransferase (GABA-AT).	3-hydroxybenzylhydrazine	0-26	4-aminobutyrate aminotransferase	Homo sapiens	152-192
8576911-1	1996	(3-Hydroxybenzyl)hydrazine and methylhydrazine have been found to be potent slow-binding inhibitors of the pyridoxal 5-phosphate (PLP)-dependent enzyme gamma-aminobutyric acid aminotransferase (GABA-AT).	3-hydroxybenzylhydrazine	0-26	4-aminobutyrate aminotransferase	Homo sapiens	194-201
8761019-2	1996	TH activity was determined in tissue extracts by measuring the accumulation of L-DOPA following administration of the dopa decarboxylase inhibitor, NSD-1015.	3-hydroxybenzylhydrazine	148-156	tyrosine 3-monooxygenase	Mesocricetus auratus	0-2
8761019-2	1996	TH activity was determined in tissue extracts by measuring the accumulation of L-DOPA following administration of the dopa decarboxylase inhibitor, NSD-1015.	3-hydroxybenzylhydrazine	148-156	aromatic-L-amino-acid decarboxylase	Mesocricetus auratus	118-136
8991801-1	1995	In PC12 rat pheochromocytoma cells differentiated with nerve growth factor (NGF), neuropeptide Y inhibited depolarization-stimulated catecholamine synthesis as determined by in situ measurement of 3,4-dihydroxyphenylalanine (DOPA) production in the presence of the decarboxylase inhibitor m-hydroxybenzylhydrazine (NSD-1015).	3-hydroxybenzylhydrazine	289-313	neuropeptide Y	Rattus norvegicus	82-96
8991801-1	1995	In PC12 rat pheochromocytoma cells differentiated with nerve growth factor (NGF), neuropeptide Y inhibited depolarization-stimulated catecholamine synthesis as determined by in situ measurement of 3,4-dihydroxyphenylalanine (DOPA) production in the presence of the decarboxylase inhibitor m-hydroxybenzylhydrazine (NSD-1015).	3-hydroxybenzylhydrazine	315-323	neuropeptide Y	Rattus norvegicus	82-96
7570352-6	1995	Twenty-four hours after cessation of treatment, dopamine synthesis, measured as accumulation of 3,4-dihydroxyphenylalanine (DOPA) after treatment with the DOPA decarboxylase inhibitor NSD-1015, was enhanced in the striatum, but not nucleus accumbens-olfactory tubercle (NAOT) or ventral mesencephalon (VM).	3-hydroxybenzylhydrazine	184-192	dopa decarboxylase	Rattus norvegicus	155-173
7648206-4	1995	UV-visible and 1H NMR studies, both with GABA aminotransferase and with PLP as a chemical model for the enzyme-catalyzed reaction, indicate that 3-hydroxybenzylhydrazine reacts both enzymatically and nonenzymatically to form the 3-hydroxybenzylhydrazone of PLP without tautomerization.	3-hydroxybenzylhydrazine	145-169	4-aminobutyrate aminotransferase	Sus scrofa	41-62
7648206-3	1995	3-Hydroxybenzylhydrazine is shown to be a potent in vitro time-dependent inhibitor of pig brain GABA aminotransferase.	3-hydroxybenzylhydrazine	0-24	4-aminobutyrate aminotransferase	Sus scrofa	96-117
7722654-6	1995	Moreover, the addition of a DOPA decarboxylase inhibitor (30 microM NSD-1015) increased the formation of TOPA compounds in both the unstimulated and stimulated conditions to a maximum of 5.5 +/- 0.7 pmol/10(6) cells after a 45 min incubation.	3-hydroxybenzylhydrazine	68-76	dopa decarboxylase	Rattus norvegicus	28-46
1997791-4	1991	An increase in the perfusate concentration of p-tyrosine resulted in a significant increase in p-tyramine production that was blocked by the addition of NSD-1015, an inhibitor of aromatic-1-amino decarboxylase (AADC).	3-hydroxybenzylhydrazine	153-161	dopa decarboxylase	Rattus norvegicus	179-209
8096696-0	1993	Inhibition of aromatic L-amino acid decarboxylase under physiological conditions: optimization of 3-hydroxybenzylhydrazine concentration to prevent concurrent inhibition of monoamine oxidase.	3-hydroxybenzylhydrazine	98-122	dopa decarboxylase	Canis lupus familiaris	14-49
8096696-2	1993	This study was done to determine if the concentration of the hydrazine derivative 3-hydroxybenzylhydrazine (NSD-1015), a drug frequently used in vitro to inhibit AAAD, could be adjusted such that it would inhibit that enzyme, but would not simultaneously inhibit a second, potentially important enzyme, monoamine oxidase (MAO; EC 1.4.3.4).	3-hydroxybenzylhydrazine	82-106	dopa decarboxylase	Canis lupus familiaris	162-166
8096696-2	1993	This study was done to determine if the concentration of the hydrazine derivative 3-hydroxybenzylhydrazine (NSD-1015), a drug frequently used in vitro to inhibit AAAD, could be adjusted such that it would inhibit that enzyme, but would not simultaneously inhibit a second, potentially important enzyme, monoamine oxidase (MAO; EC 1.4.3.4).	3-hydroxybenzylhydrazine	108-116	dopa decarboxylase	Canis lupus familiaris	162-166
8096696-6	1993	The efficacy of NSD-1015 in inhibiting AAAD and MAO was determined by examining the levels of DOPA and DOPEG, respectively.	3-hydroxybenzylhydrazine	16-24	dopa decarboxylase	Canis lupus familiaris	39-43
1501771-2	1992	3-hydroxybenzylhydrazine, a central inhibitor of DOPA decarboxylase, or similarly with intraventricular 6-hydroxydopamine.	3-hydroxybenzylhydrazine	0-24	dopa decarboxylase	Rattus norvegicus	49-67
1348847-1	1992	DOPA was measured in the anterior pituitary and hypothalamic-hypophysial portal blood after treatment with NSD-1015, a DOPA decarboxylase inhibitor.	3-hydroxybenzylhydrazine	107-115	dopa decarboxylase	Rattus norvegicus	119-137
1997791-4	1991	An increase in the perfusate concentration of p-tyrosine resulted in a significant increase in p-tyramine production that was blocked by the addition of NSD-1015, an inhibitor of aromatic-1-amino decarboxylase (AADC).	3-hydroxybenzylhydrazine	153-161	dopa decarboxylase	Rattus norvegicus	211-215
2141990-2	1990	All animals were also treated with the 5-HTP and DOPA decarboxylase inhibitor NSD-1015, 100 mg kg-1 SC, 30 min before decapitation.	3-hydroxybenzylhydrazine	78-86	dopa decarboxylase	Rattus norvegicus	49-67
34313482-3	2021	Treatment with L-dihydroxyphenylalanine, not tyrosine, caused the production of dopamine in the incubation of INS-1 cells (rat islet beta cell line) and primary isolated islets, which was blocked by AADC inhibitor NSD-1015.	3-hydroxybenzylhydrazine	214-222	dopa decarboxylase	Rattus norvegicus	199-203
34313482-8	2021	Inhibiting TH with AMPT blocked bethanechol chloride-induced increases in L-dihydroxyphenylalanine and dopamine, while inhibiting AADC with NSD-1015 only blocked the dopamine increase.	3-hydroxybenzylhydrazine	140-148	dopa decarboxylase	Rattus norvegicus	130-134
2765866-7	1989	After pretreatment with NSD-1015, a central DOPA decarboxylase inhibitor, behavioral change was also elicited, although DA was still not increased.	3-hydroxybenzylhydrazine	24-32	dopa decarboxylase	Rattus norvegicus	44-62
3141816-1	1988	The accumulation rates of 3,4"-dihydroxyphenylalanine (DOPA) and 5-hydroxytryptophan (5-HTP) after inhibition of aromatic amino acid decarboxylase (AADC) by 3-hydroxybenzylhydrazine (NSD 1015) or 1-(DL-seryl)-2- (2,3,4-trihydroxybenzyl)hydrazine (Ro 4-4602) have widely been used as measurements of the in vivo synthesis rates of monoamines.	3-hydroxybenzylhydrazine	157-181	dopa decarboxylase	Rattus norvegicus	122-146
3141816-1	1988	The accumulation rates of 3,4"-dihydroxyphenylalanine (DOPA) and 5-hydroxytryptophan (5-HTP) after inhibition of aromatic amino acid decarboxylase (AADC) by 3-hydroxybenzylhydrazine (NSD 1015) or 1-(DL-seryl)-2- (2,3,4-trihydroxybenzyl)hydrazine (Ro 4-4602) have widely been used as measurements of the in vivo synthesis rates of monoamines.	3-hydroxybenzylhydrazine	157-181	dopa decarboxylase	Rattus norvegicus	148-152
6440044-2	1984	Sagittal hypothalamic slices of ovariectomized rats were incubated in a medium containing 3-hydroxybenzylhydrazine (NSD 1015), an inhibitor of DOPA decarboxylase.	3-hydroxybenzylhydrazine	90-114	dopa decarboxylase	Rattus norvegicus	143-161
6504328-1	1984	Dopamine (DA) elevations in rat striatum produced by combined administration of L-dopa and carbidopa were abolished when L-dopa was injected with NSD-1015, an inhibitor of central dopa-decarboxylase.	3-hydroxybenzylhydrazine	146-154	dopa decarboxylase	Rattus norvegicus	180-198
6529603-1	1984	Further studies of the histamine metabolism in the M-2 adenocarcinoma have shown that the tumor and the intestinal histidine decarboxylase should have similar conformations, since both enzymes exhibit superimposable curves of activity vs. pH as well as nearly identical 50% inhibitory concentrations for the specific inhibitor NSD-1015.	3-hydroxybenzylhydrazine	327-335	histidine decarboxylase	Homo sapiens	115-138
32522342-6	2020	Importantly, treatment with AADC inhibitor NSD-1015 significantly ameliorated EAP-elicited pain response and catecholamine overactivity in MTA1-/- mice.	3-hydroxybenzylhydrazine	43-51	dopa decarboxylase	Mus musculus	28-32
32522342-6	2020	Importantly, treatment with AADC inhibitor NSD-1015 significantly ameliorated EAP-elicited pain response and catecholamine overactivity in MTA1-/- mice.	3-hydroxybenzylhydrazine	43-51	metastasis associated 1	Mus musculus	139-143
2303915-7	1990	Hearts and spleens from -Cu mice appeared to have higher tyrosine 3-monooxygenase activity as judged by increasing rates of L-dihydroxyphenylalanine accumulation following injection of m-hydroxybenzylhydrazine (NSD-1015), an inhibitor of aromatic amino acid decarboxylase.	3-hydroxybenzylhydrazine	185-209	tyrosine hydroxylase	Mus musculus	57-81
2303915-7	1990	Hearts and spleens from -Cu mice appeared to have higher tyrosine 3-monooxygenase activity as judged by increasing rates of L-dihydroxyphenylalanine accumulation following injection of m-hydroxybenzylhydrazine (NSD-1015), an inhibitor of aromatic amino acid decarboxylase.	3-hydroxybenzylhydrazine	211-219	tyrosine hydroxylase	Mus musculus	57-81
3925083-7	1985	The accumulation rate of 3,4-dihydroxyphenylalanine (DOPA) in vivo in the retina of diabetic rats, measured following the administration of the AADC inhibitor m-hydroxybenzyl-hydrazine (100 mg/kg i.p.	3-hydroxybenzylhydrazine	159-184	dopa decarboxylase	Rattus norvegicus	144-148
32671919-11	2020	In addition, l-dopa reduced corticotrophin-releasing hormone-stimulated adrenocorticotrophic hormone release from these cells after AADC activity was inhibited by NSD-1015.	3-hydroxybenzylhydrazine	163-171	dopa decarboxylase	Mus musculus	132-136